A Single and Repeat Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of GSK1223249 in Patients With ALS.

Trial Profile

A Single and Repeat Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of GSK1223249 in Patients With ALS.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Ozanezumab (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 10 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 23 Jun 2011 Planned end date changed from 1 Aug 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top